# SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

> **NCT05814354** · PHASE3 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 530 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel

## Key facts

- **NCT ID:** NCT05814354
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-30
- **Primary completion:** 2025-01-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 530 (ESTIMATED)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05814354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05814354, "SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05814354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*